/
BGLC
$2.03-$0.04 (-1.93%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.0M
2M shares
52-week range
$1.07 – $15.60
7% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
12.85%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-253.57
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $212.3K | $127.0K | $11.4M | $13.4M | $10.9M | $9.8M | $9.5M | $7.4M |
| Cost of revenue | $183.6K | $71.1K | $9.7M | $11.2M | $9.7M | $8.4M | $8.2M | $6.3M |
| Gross profit | $28.8K | $55.9K | $1.7M | $2.2M | $1.3M | $1.3M | $1.3M | $1.1M |
| Gross margin | 13.5% | 44.0% | 15.1% | 16.4% | 11.5% | 13.6% | 13.6% | 14.6% |
| R&D | $0 | $0 | $0 | $0 | $0 | $55.0K | $47.5K | $50.7K |
| Operating income | $59.9K | −$275.7K | $1.3M | $1.1M | −$291.2K | −$2.6M | −$1.6M | −$3.2M |
| EBITDA | $100.5K | −$222.4K | $1.4M | $1.2M | −$185.8K | −$2.5M | −$1.4M | −$2.8M |
| Net income | $26.5K | −$246.5K | $1.1M | $751.6K | −$356.0K | −$2.6M | −$1.6M | −$3.0M |
| Net margin | 12.5% | -194.1% | 9.6% | 5.6% | -3.3% | -26.9% | -16.8% | -40.2% |
| EPS (diluted) | 0.00 | -0.03 | 1.28 | 0.53 | -0.25 | -1.53 | -0.90 | -1.61 |
Annual figures · source: Financial Modeling Prep
Peer comparison
BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
www.bionexusgenelab.com- Employees
- 1
- IPO / List date
- Mar 11, 2020
- HQ
- KUALA LUMPUR, N8
Held by traders on TradeandTell
No one on the platform currently holds BGLC.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BGLC as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-04-07 | 1-for-10reverse |
| 2023-07-20 | 1-for-12reverse |
Recent trades on TradeandTell
No one on the platform has traded BGLC yet.
